Logo.png
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
October 05, 2023 08:45 ET | GRI Bio, Inc.
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting Data supports GRI Bio’s...
Logo.png
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 09:05 ET | GRI Bio, Inc.
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
Logo.png
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
August 23, 2023 09:00 ET | GRI Bio, Inc.
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation...
Logo.png
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 08:05 ET | GRI Bio, Inc.
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment...
Logo.png
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
August 07, 2023 08:35 ET | GRI Bio, Inc.
Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...
Logo.png
GRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference
August 03, 2023 08:30 ET | GRI Bio, Inc.
- Live moderated webcast fireside chat today, August 3rd at 11:15 AM ET LA JOLLA, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology...
Logo.png
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
July 24, 2023 09:00 ET | GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...
Logo.png
GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023 08:45 ET | GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio, Inc. management team on Tuesday, July 11th at 2:00 PM ET LA JOLLA, CA, July 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...
Logo.png
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
June 27, 2023 08:45 ET | GRI Bio, Inc.
- U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) - Company building a robust global patent estate LA JOLLA, CA, June...
Logo.png
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
June 13, 2023 08:35 ET | GRI Bio, Inc.
Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc....